お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
918155

世界のHIV診断および治療市場:2019年~2025年の予測

Global HIV Diagnostics and Treatment Market 2019-2025

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
世界のHIV診断および治療市場:2019年~2025年の予測
出版日: 2019年10月07日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは世界のHIV診断および治療市場について調査しており、市場機会、成長および阻害要因、検査タイプ・診断製品・治療・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 レポートの概要

  • 調査方法・ツール
  • 市場分析
    • セグメント別
    • 地域別
    • 利害関係者別

第2章 市場の概要および洞察

  • レポートの範囲
  • アナリストの洞察および現在の市場動向
    • 主な調査結果
    • 提言
    • 結論
  • 規則・規制

第3章 競合情勢

  • 企業シェア分析
  • 主要戦略分析
  • 主要企業分析
    • Bristol-Myers Squibb Co.
    • Merck & Co., Inc.
    • GlaxoSmithKline PLC
    • Gilead Sciences, Inc.
    • ViiV Healthcare

第4章 市場の決定要因

  • 成長要因
  • 阻害要因
  • 市場機会

第5章 市場セグメンテーション

  • 検査タイプ別
    • 抗体検査
    • ウイルス同定アッセイ
    • CD4検査
    • ウイルス負荷試験
    • 早期乳児診断
  • 診断製品別
    • キット・試薬
    • 機器
  • 治療別
    • 非ヌクレオシド系逆転写酵素阻害剤(NNRTIS)
    • ヌクレオシドまたはヌクレオチド逆転写酵素阻害剤(NRTIS)
    • インテグラーゼ阻害剤
    • その他(プロテアーゼ阻害剤(PIS))
  • エンドユーザー別
    • 診断検査室
    • 病院
    • 血液バンク
    • ホームケア
    • その他(学術研究機関)

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • その他
  • その他の地域

第7章 企業プロファイル

  • Abbott Laboratories
  • AbbVie Inc.
  • Becton, Dickinson and Co.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hologic, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Pfizer Inc.
  • QIAGEN N.V.
  • Siemens AG
  • Sysmex Corp.
  • ViiV Healthcare
図表

LIST OF TABLES

  • 1. GLOBAL HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2018-2025 ($ MILLION)
  • 2. GLOBAL ANTIBODY TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 3. GLOBAL VIRAL IDENTIFICATION ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL CD4 TESTING RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 5. GLOBAL VIRAL LOAD TESTING RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 6. GLOBAL EARLY INFACT DIAGNOSTICS RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC PRODUCT, 2018-2025 ($ MILLION)
  • 8. GLOBAL KITS AND REAGENTS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 9. GLOBAL INSTRUMENTS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 10. GLOBAL HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 11. GLOBAL NNRTIS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 12. GLOBAL NRTIS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 13. GLOBAL INTEGRASE INHIBITORS RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 14. GLOBAL OTHER PRODUCTS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 15. GLOBAL HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 16. GLOBAL DIAGNOSTIC LABORATORY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 17. GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 18. GLOBAL BLOOD BANKS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 19. GLOBAL HOME CARE SETTINGS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 20. GLOBAL OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 21. GLOBAL HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 22. NORTH AMERICA HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 23. NORTH AMERICAN HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2018-2025 ($ MILLION)
  • 24. NORTH AMERICAN HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC PRODUCT, 2018-2025 ($ MILLION)
  • 25. NORTH AMERICAN HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 26. NORTH AMERICAN HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 27. EUROPEAN HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 28. EUROPEAN HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2018-2025 ($ MILLION)
  • 29. EUROPEAN HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC PRODUCT, 2018-2025 ($ MILLION)
  • 30. EUROPEAN HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 31. EUROPEAN HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 32. ASIA-PACIFIC HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 33. ASIA-PACIFIC HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2018-2025 ($ MILLION)
  • 34. ASIA-PACIFIC HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS PRODUCT, 2018-2025 ($ MILLION)
  • 35. ASIA-PACIFIC HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 36. ASIA-PACIFIC HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 37. REST OF THE WORLD HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2018-2025 ($ MILLION)
  • 38. REST OF THE WORLD HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOTIC PRODUCT, 2018-2025 ($ MILLION)
  • 39. REST OF THE WORLD HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 40. REST OF THE WORLD HIV DIAGNOSTICS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL HIV DIAGNOSTICS AND TREATMENT MARKET SHARE BY TEST TYPE, 2018 VS 2025 (%)
  • 2. GLOBAL HIV DIAGNOSTICS AND TREATMENT MARKET SHARE BY DIAGNOSTIC PRODUCT, 2018 VS 2025 (%)
  • 3. GLOBAL HIV DIAGNOSTICS AND TREATMENT MARKET SHARE BY TREATMENT, 2018 VS 2025 (%)
  • 4. GLOBAL HIV DIAGNOSTICS AND TREATMENT MARKET SHARE BY END-USER, 2018 VS 2025 (%)
  • 5. GLOBAL HIV DIAGNOSTICS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 6. US HIV DIAGNOSTICS AND TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. CANADA HIV DIAGNOSTICS AND TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. UK HIV DIAGNOSTICS AND TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. FRANCE HIV DIAGNOSTICS AND TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. GERMANY HIV DIAGNOSTICS AND TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. ITALY HIV DIAGNOSTICS AND TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. SPAIN HIV DIAGNOSTICS AND TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. ROE HIV DIAGNOSTICS AND TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. INDIA HIV DIAGNOSTICS AND TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. CHINA HIV DIAGNOSTICS AND TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 16. JAPAN HIV DIAGNOSTICS AND TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 17. REST OF ASIA-PACIFIC HIV DIAGNOSTICS AND TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 18. REST OF THE WORLD HIV DIAGNOSTICS AND TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
目次
Product Code: OMR2019913

Title:
Global HIV Diagnostics and Treatment
Market Size, Share & Trends Analysis Report by Test Type (Antibody Test, Viral Identification Assays, CD4 Testing, Viral Load Testing, and Early Infant Diagnostics), by Diagnostic Product (Kits and Reagents, and Instruments), by Treatment (Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIS), Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTIS), Integrase Inhibitors, and Others), and by End-User (Diagnostic Laboratory, Hospitals, Home Care Settings, Blood Bank, and Others) and Forecast 2019-2025.

The global HIV diagnostics and treatment market is expected to grow at a CAGR of 7.6% during the forecast period. The HIV impact on the immune system of human body weakens the patient's defense system against any infections. It attacks and destroys white blood cell and T-helper cell. Progressively the immune system becomes vulnerable to any kind of infections. The market for HIV is growing considerably owing to increasing occurrence of HIV/AIDS infection around the globe. The government is taking initiatives for diagnosis and treatment, blood transfusions, and is significantly working on rising awareness regarding HIV/AIDS. The major factors that are responsible for the rising number of HIV infection includes lifestyle changes, unsafe injection drug usage and lack of awareness.

Geographically, the global aluminum foil market is classified into North America, Europe, Asia-Pacific, and Rest of the World. North America contributes a significant share in the global HIV diagnosis and treatment market due to the significant R&D activities for HIV/AIDS diagnosis and treatment. Regional government is taking initiatives for the ongoing diagnostic efforts for development of new treatment and products. Asia-Pacific is anticipated to grow at considerable pace in the global market during the forecast period. The partnerships among the western market players and the government in the region are major factors that are fueling the growth of HIV diagnosis and treatment market in the region.

The main players functioning in the global HIV diagnosis and treatment market include Bristol-Myers Squibb Co., Merck & Co., Inc., GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd., bioMerieux SA, Gilead Sciences, Inc., Siemens AG, Sysmex Corp., and ViiV Healthcare. These players are playing a significant role in the growth of the HIV diagnosis and treatment market by providing various products and adopting several strategies such as a merger and acquisition, partnerships, collaboration, R&D; among others.

Research Methodology

The market study of the global HIV diagnostics and treatment market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Forward looking statements from key market players
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for HIV diagnostics and treatment market players, pharmaceutical companies, research institutes, and government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • 1. Global HIV Diagnostics and Treatment Market Research and Analysis by Test Type
  • 2. Global HIV Diagnostics and Treatment Market Research and Analysis by Diagnostic Product
  • 3. Global HIV Diagnostics and Treatment Market Research and Analysis by Treatment
  • 4. Global HIV Diagnostics and Treatment Market Research and Analysis by End-User

The Report Covers:

  • Comprehensive Research Methodologyof the global HIV diagnostics & treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global HIV diagnostics and treatment market.
  • Insights about market determinants which are stimulating the global HIV diagnostic and treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Bristol-Myers Squibb Co.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Merck & Co., Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. GlaxoSmithKline PLC
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Gilead Sciences, Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. ViiV Healthcare
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global HIV Diagnostics and Treatment Market by Test Type
    • 5.1.1. Antibody Tests
      • 5.1.1.1. HIV-1 Screening Tests
      • 5.1.1.2. HIV-1 Antibody Confirmatory Tests
      • 5.1.1.3. HIV-2 & Group O Diagnostics Tests
    • 5.1.2. Viral Identification Assays
    • 5.1.3. CD4 Testing
    • 5.1.4. Viral Load Testing
    • 5.1.5. Early Infant Diagnostics
  • 5.2. Global HIV Diagnostics and Treatment Market by Diagnostics Products
    • 5.2.1. Kits and Reagents
    • 5.2.2. Instruments
  • 5.3. Global HIV Diagnostics and Treatment Market by Treatment
    • 5.3.1. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIS)
    • 5.3.2. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTIS)
    • 5.3.3. Integrase Inhibitors
    • 5.3.4. Others (Protease Inhibitors (PIS))
  • 5.4. Global HIV Diagnostics and Treatment Market by End-User
    • 5.4.1. Diagnostics Laboratory
    • 5.4.2. Hospitals
    • 5.4.3. Blood Banks
    • 5.4.4. Home Care Settings
    • 5.4.5. Others (Academic and Research Institutes)

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. AbbVie Inc.
  • 7.3. Becton, Dickinson and Co.
  • 7.4. Bio-Rad Laboratories, Inc.
  • 7.5. bioMerieux SA
  • 7.6. Boehringer Ingelheim International GmbH
  • 7.7. Bristol-Myers Squibb Co.
  • 7.8. Cipla Inc.
  • 7.9. F. Hoffmann-La Roche Ltd.
  • 7.10. Gilead Sciences, Inc.
  • 7.11. GlaxoSmithKline PLC
  • 7.12. Hologic, Inc.
  • 7.13. Johnson & Johnson Services, Inc.
  • 7.14. Merck & Co., Inc.
  • 7.15. Mylan N.V.
  • 7.16. Pfizer Inc.
  • 7.17. QIAGEN N.V.
  • 7.18. Siemens AG
  • 7.19. Sysmex Corp.
  • 7.20. ViiV Healthcare
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.